DTIL

Precision Biosciences is a clinical-stage gene editing company developing in vivo gene editing therapies using its proprietary ARCUS platform, which utilizes a novel endonuclease technology designed to perform sophisticated gene edits including insertion, elimination, and excision delivered via adeno-associated virus vectors. The company's lead program, PBGENE-HBV, is a wholly-owned in vivo gene editing therapy in a first-in-human clinical trial targeting chronic hepatitis B infection through elimination of viral DNA, representing the first potentially curative gene editing approach designed to target the root cause of the disease.

Pipeline

Catalyst Calendar